NCT06352008 2025-11-20
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06258642 2025-08-20
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Fudan University
Phase NA Recruiting
NCT04136535 2025-07-22
PCA
Fudan University
Phase 2 Recruiting
NCT06379087 2025-07-10
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT07037680 2025-07-09
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06355609 2024-09-20
WUKONG-32-RW
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT06348927 2024-09-19
WUKONG-32
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT04322617 2024-06-04
ATHENA
Hunan Province Tumor Hospital
Phase 2/3 Recruiting
NCT06188650 2024-01-03
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
Ningbo Medical Center Lihuili Hospital
Phase NA Recruiting
NCT06043973 2023-09-21
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Qianfoshan Hospital
Phase 3 Recruiting